Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $1.08 and last traded at $1.08, with a volume of 35222 shares. The stock had previously closed at $1.13.
A number of brokerages have issued reports on ALIM. ValuEngine raised Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a report on Friday, October 27th. Finally, Cowen reaffirmed a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Alimera Sciences has an average rating of “Hold” and an average target price of $3.38.
The stock has a market capitalization of $75.37, a price-to-earnings ratio of -3.52 and a beta of 1.79. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65.
An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. increased its position in Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 180,300 shares of the biopharmaceutical company’s stock after purchasing an additional 35,200 shares during the period. PNC Financial Services Group Inc. owned 0.28% of Alimera Sciences worth $251,000 at the end of the most recent quarter. Institutional investors own 41.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/02/10/alimera-sciences-alim-reaches-new-1-year-low-at-1-08.html.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.